Sana Biotechnology (SANA) Gains from Investment Securities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Gains from Investment Securities data on file, last reported at $10.7 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 476.45% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $27.6 million (up 972.28% YoY), and the FY2025 full-year result was $14.8 million, up 2411.91% from the prior year.
• Gains from Investment Securities rose to $10.7 million in Q1 2026, from $8.6 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $10.7 million in Q1 2026 to a low of -$58.6 million in Q3 2023.
• A 5-year average of -$505117.6 and a median of $3.4 million in 2024 frame the typical range for Gains from Investment Securities.
• Peak annual rise in Gains from Investment Securities reached 1134.09% in 2023, while the deepest fall reached 606.02% in 2023.
• Tracing SANA's Gains from Investment Securities over 5 years: stood at $9.2 million in 2022, then plunged by 30.26% to $6.4 million in 2023, then tumbled by 144.78% to -$2.9 million in 2024, then surged by 396.99% to $8.6 million in 2025, then increased by 25.28% to $10.7 million in 2026.
• Business Quant data shows SANA's Gains from Investment Securities at $10.7 million in Q1 2026, $8.6 million in Q4 2025, and $2.0 million in Q3 2025.